Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
NCT05008276 · View on ClinicalTrials.gov ↗
Study Summary
Early diabetic kidney disease (DKD) occurs in 50-70% of youth with type 2 diabetes (T2D) and confers high lifetime risk of dialysis and premature death. Youth-onset T2D typically manifests during or shortly after puberty in adolescents with obesity. Epidemiological data implicate puberty as an accelerator of kidney disease in youth with obesity and diabetes and the investigators posit that the link between puberty and T2D-onset may explain the high burden of DKD in youth-onset T2D. A better understanding of the impact of puberty on kidney health is needed to promote preservation of native kidney function, especially in youth with T2D.
Conditions Studied
Interventions
- DRUG Aminohippurate Sodium Inj 20%
- DRUG Iohexol Inj 300 MG/ML
- DRUG Dextran 40
Study Locations (2)
Colorado
- Children's Hospital Colorado — Aurora
Washington
- Seattle Children's Hospital — Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-09-27 |
| Est. Completion | 2027-12-01 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05008276
The ClinicalTrials.gov registry entry for NCT05008276 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Petter Bjornstad, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 6 conditions, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 3 interventions — of which Aminohippurate Sodium Inj 20% is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05008276 reports 2 study locations spanning 2 distinct geographic areas — top geographies include Colorado, Washington. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05008276 about?
NCT05008276 is a clinical study titled "Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)". Early diabetic kidney disease (DKD) occurs in 50-70% of youth with type 2 diabetes (T2D) and confers high lifetime risk of dialysis and premature death. Youth-onset T2D typically manifests during or shortly after puberty in adolescents with obesity. Epidemiological data implicate puberty as an accel...
What is the current status of trial NCT05008276?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2021-09-27. Estimated completion is 2027-12-01.
What conditions does trial NCT05008276 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Pre Diabetes, Adolescent Obesity, Puberty. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05008276?
The interventions under investigation include: Aminohippurate Sodium Inj 20% (DRUG), Iohexol Inj 300 MG/ML (DRUG), Dextran 40 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05008276?
This trial is sponsored by Petter Bjornstad, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05008276 being conducted?
This trial has 2 study locations across Colorado, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.